NMRD - Nemaura Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0600
-0.0200 (-1.85%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.0800
Open1.0900
Bid0.00 x 1200
Ask0.00 x 1300
Day's Range1.0500 - 1.1100
52 Week Range0.8000 - 5.8000
Volume84,635
Avg. Volume137,688
Market Cap219.992M
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Nemaura Reports Third Quarter 2018 Financial Results

    Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive,.

  • GlobeNewswire9 days ago

    Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development

    February 11, 2019 – Nemaura Medical, Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Fred Schaebsdau, MD, PhD, MBA has joined Nemaura to lead strategy and business development. Dr. Schaebsdau will advance Nemaura’s commercial strategy for its planned launch of SugarBEAT® in Europe, and advise regarding its upcoming 510(k) submission to the United States Food and Drug Administration.

  • GlobeNewswire13 days ago

    Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

    February 7, 2019 – Nemaura Medical Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, today announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte. SugarBEAT® CGM utilizes a proprietary, daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.

  • GlobeNewswirelast month

    Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

    Loughborough, England –Nemaura Medical, Inc. (NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has substantially advanced the use-case for SugarBEAT® to improve management of glucose levels by spending more time in range. SugarBEAT® CGM utilizes a proprietary daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day. Nemaura has previously achieved industry-leading, skin-patch warm-up periods of less than one hour meaning that reliable glucose readings can be expected one hour after application of the skin-patch.

  • GlobeNewswire2 months ago

    Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that two of the three key stages for the CE Mark approval of sugarBEAT® have been completed. Dr. Faz Chowdhury, CEO of Nemaura, will host an investor webinar and live Q&A at 10am ET today.

  • GlobeNewswire2 months ago

    Dawson James Securities Announces Closing of $2.0 Million Offering for Nemaura Medical, Inc.

    BOCA RATON, Fla., Dec. 20, 2018 -- Dawson James Securities, Inc. in conjunction with Nemaura Medical (Nasdaq: NMRD) announced today the closing of a public offering of.

  • GlobeNewswire2 months ago

    Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments

    LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose.

  • Why Micro Cap Nemaura Medical Crashed 39.5% Today
    Motley Fool2 months ago

    Why Micro Cap Nemaura Medical Crashed 39.5% Today

    The clinical-stage upstart is raising money via a stock offering that dilutes existing investors.

  • GlobeNewswire2 months ago

    Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today published clinical data from its recently completed study intended to support a De Novo submission to the U.S Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product. The global addressable market for CGM is estimated at $82B per annum, with the U.S. the largest single market estimated at $13B.

  • GlobeNewswire2 months ago

    Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced the pricing of a "best efforts" public offering of  Company's shares of common stock and warrants with expected total gross proceeds of up to $2.5 million. The offering is expected to close on or about December 20, 2018, subject to satisfaction of customary closing conditions. The offering was priced at $1.04 per share of common stock, with each share coupled with one five-year warrant to purchase one share of common stock, at an exercise price of $1.04 per share.

  • GlobeNewswire2 months ago

    Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin

    Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that the Advanced Technologies and Treatments for Diabetes (ATTD) Conference has accepted its sugarBEAT® Clinical Performance Data Abstract for poster presentation at Berlin in February 2019. ATTD is the leading international forum for clinicians to present and discuss the use of new technologies with the goal of improving the care of people with diabetes at the fastest possible pace, and has become synonymous with top calibre scientific programs. Nemaura has also recently completed the clinical studies required for sugarBEAT® FDA De Novo 510(k) submission, and anticipates publishing this data on its website in the coming weeks, and submitting for FDA approval in March 2019.

  • GlobeNewswire3 months ago

    Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission

    Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today reported that it has successfully completed the clinical studies needed to support a De-Novo 510(k) submission to the U.S. Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product. The global addressable market for CGM is estimated at $82B per annum, with the U.S. market estimated at $13.5B.

  • Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday
    Motley Fool5 months ago

    Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday

    The clinical-stage upstart is making progress in advancing a new type of glucose monitor to market.